Board of Directors
The principal duty of the Board is to represent and protect the interests of the Company's shareholders by ensuring that the Company is well-managed in the interests of its shareholders. In doing so, the Board has the legal responsibility for overseeing the affairs of the Company. The Board's oversight function is exercised through the nomination, election and appointment of competent directors.
The Board remains responsible for oversight and has an obligation to keep informed in order to assist Management in formulating, developing and implementing plans and serves as a body to review and provide advice to Management on the operations of the Company. These duties are discharged by the full Board, the Board's Committees and by individual members of the Board, as may be appropriate relative to the circumstance.
Additional information on Board composition, committees, processes, information and functions can be found in the 2010 Annual Report and Accounts in the Financial Information section and also in the Corporate Governance section.
Dr Peter Fellner joined Optos as Chairman on 1 January 2010. From 1990 to 2003 he served as CEO of Celltech Group Plc and oversaw its growth into the UK's largest biotechnology company. Dr Fellner then served as Celltech's Chairman until its acquisition in 2004. Before this he served as CEO of Roche UK from 1986 to 1990, having previously been Director of the UK Roche Research Centre. Dr Fellner currently serves as Chairman of the medical technology company Consort Medical Plc and the biotechnology companies Vernalis Plc, Biotie Therapies Corp and Ablynx nv. He was Vice‑Chairman of Astex Pharmaceuticals Inc until its acquisition by Otsuka in October 2013. He is also a Director of the global biopharmaceutical company UCB SA and is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of the biotechnology company Acambis Plc and Premier Research Group Plc, a CRO, until they were each acquired during 2008, and was also a Director of Evotec AG until 2011.
Roy Davis joined Optos as Chief Executive Officer on 17 November 2008. He was CEO of Gyrus Group plc, a leading medical device company, from 2007 before it was acquired by the Olympus Corporation of Japan in 2008. Before this, Mr Davis served as Chief Operating Officer of Gyrus from 2003. He joined Gyrus as a Non-executive Director on its flotation in 1997. Prior to this, Mr Davis was CEO of NTERA, a nanotechnology company, and spent almost ten years with Arthur D Little, the global management consulting company, where he was Vice President and Global Head of its operations management business. He has also held senior positions for Tricom, Reuters and Molex. Mr Davis holds a mechanical engineering degree and a MBA from the London Business School.
Robert Kennedy joined the Company in August 2011 and holds the positions of Chief Financial Officer and Company Secretary.
Mr Kennedy joined from the University of Dundee where he had been the Director of Finance since 2007. Prior to this, Mr Kennedy held a number of senior finance roles including six years with Gamma Holding NV, the last three as Group Finance Director of the Filtration Division. He also spent three years working at PricewaterhouseCoopers as a Management Consultant.
Mr Kennedy has an honours degree in economics from the University of Sheffield and a MBA from the University of Manchester. He is a member of the Chartered Institute of Management Accountants and the Association of Corporate Treasurers.
John Goddard joined Optos as Non-executive Director in June 2011 and serves as Chairman of the Audit Committee. He has had a distinguished career in the global pharmaceuticals industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning. Mr Goddard has extensive experience of mergers and acquisitions and had significant involvement in the merger of Astra and Zeneca. Prior to his retirement from AstraZeneca in 2010, he was responsible for building a 100-strong global team focused on M&A and licensing, which completed 75 transactions in four years, including several acquisitions, in-licensing and out-licensing of compounds and disposals. Latterly, Mr Goddard became Chairman of the AstraZeneca subsidiary Aptium Oncology and of the substantial medical device business, Astratech. He is a member of the Board of Directors of Intas Pharmaceuticals Ltd and a non-executive director of Oxford Pharmascience Group Plc. Mr Goddard is a Fellow of the Institute of Chartered Accountants and a Member of the Association of Corporate Treasurers.
Dr Peter Kehoe joined Optos as Non-executive Director in October 2010. He has been a principal of Kehoe Eye Care, US since 1984 and a consultant to Transitions Optical and Diopsys, Inc. since 2010 and 2012 respectively. Dr Kehoe served on the Board of Trustees of the American Optometric Association from 1999 to 2010 and was instrumental in the launch of InfantSEE®, a programme offering comprehensive free eye examinations for any child in America in their first year of life. He served as President in 2008 to 2009 and currently serves as Treasurer of the World Council of Optometry. He holds an OD degree and a Doctor of Science from the Illinois College of Optometry, is a Fellow in the American Academy of Optometry and a Diplomate of the American Board of Optometry.
David Wilson joined the Company as a Non-executive Director in June 2011 and serves as the Senior Independent Director to the Board. David is Chairman and founding partner of WG Partners. He has 26 years' experience in the City, most recently as Deputy Chief Executive of Matrix Corporate Capital. Previously David was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. David has held senior positions at ING Barings as Head of UK Investment Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. David is Senior Board Adviser to Sapia Partners LLP and on the Board of Governors of Harris Academy Bromley.
Rosalyn Wilton joined Optos as Non-executive Director in August 2007 and serves as Chairman of the Remuneration Committee. Until 2009 she was Chairman of Ipreo Holdings LLC, the US-based financial data and solutions group formed following the merger of i-Deal LLC and Hemscott Group Ltd. Before the merger, Rosalyn was Chief Executive Officer of Hemscott plc. She has previously served as Managing Director of Reuters Information Services and Reuters Transactions Products and was a member of the Reuters Executive Committee. Rosalyn has held non-executive directorship positions with Scottish Widows and the London International Financial Futures Exchange. She has previously served as a Senior Adviser to 3i Investments and Providence Equity Partners. She currently serves as Non-executive Director of AXA UK, AXA Insurance and AXA Wealth Management and as Non-executive Director and Chairman of Secure Health Ltd. Rosalyn holds a BSc (Hons) from the University of London.
Quote delayed 20 minutes
Share price information
Sign up for email notifications
15 - May - 2014Interim Results Announcement
Optos plcQueensferry HouseCarnegie CampusEnterprise WayDunfermlineScotland KY11 8GRUK
+44 (0) 1383 843 300+44 (0) 1383 843 337
© 2014 Optos. Optos, optos and optomap are registered trademarks of Optos plc. UWF is an Optos trademark.
Terms and Conditions |
Registered in Scotland |
Distributors Login |